Vaxart Enters Share Purchase Agreement with Lincoln Park Capital
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 17 2026
0mins
Source: Newsfilter
- Enhanced Financing Flexibility: Vaxart's share purchase agreement with Lincoln Park Capital Fund allows the company to sell up to $25 million in common stock over a 24-month period, significantly improving its financial flexibility as it advances its oral vaccine programs.
- Market Pricing Mechanism: Under the agreement, Lincoln Park is obligated to purchase shares at market prices during each sale, with no upper limit, providing Vaxart with opportunities to raise capital when market conditions are favorable, thereby optimizing its capital structure.
- No Additional Clauses: The agreement contains no warrants, rights of first refusal, or participation rights regarding future financings, ensuring Vaxart's autonomy in future fundraising efforts and reducing potential financing risks.
- Strategic Alignment: Vaxart's CFO stated that this agreement will support the execution of clinical milestones while pursuing strategic partnerships, grants, and other funding options, aiming to create long-term value for shareholders.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
